11
Jul
2019

BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

GSK’s BCMA Antibody Gets OK, Biogen Teams With Denali & A Telemedicine Megadeal
Pfizer Secures $2B for COVID-19 Vaccine, BioNTech Raises $500M, & Our Test
Standing With Fauci, Positive Moderna Vaccine Data, and Blueprint’s Megadeal
Novavax Nabs $1.6B, BD Secures Fast Antigen Test OK, & a Tribute to Tony Fauci